share information (1):
Net income (loss) $(19,359) $7,657 $(78,806) $(38,856)
Weighted-average shares used
in computing non-GAAP net
income (loss) per share 23,671 13,417 20,483 13,212
Non-GAAP net income (loss) per
share $(0.82) $0.57 $(3.85) $(2.94)
Reconciliation of GAAP income
(loss) per share attributable
to common stockholders and
non-GAAP net income (loss)
per share:
GAAP income (loss) per share
attributable to common
stockholders, basic $(0.82) $638.08 $(7.50) $(3,850.64)
Decrease due to change in
weighted-average shares
outstanding - (637.51) 3.65 3,847.96
Decrease due to exclusion of
beneficial conversion feature - - - (0.26)
Non-GAAP net income (loss) per
share $(0.82) $0.57 $(3.85) $(2.94)
GAAP weighted-average common
shares outstanding 23,671 12 10,505 11
Increase in the weighted-average
number of shares outstanding
from treating preferred shares
as if they converted into
common shares at their date
of issuance - 13,405 9,978 13,201
Weighted-average shares used in
computing non-GAAP net income
(loss) per share 23,671 13,417 20,483 13,212
(1) Non-GAAP net income (loss) per share attributable to common
stockholders and weighted-average shares used in computing non-GAAP
income (loss) per share attributable to common stockholders treats
outstanding preferred shares as if they were converted into common
shares at their date of
'/>"/>
| SOURCE Jazz Pharmaceuticals, Inc. Copyright©2007 PR Newswire. All rights reserved |